Inquiry Basket
Loading ......
A broad spectrum of vision-threatening retinal disorders arises from unregulated pathological angiogenesis and excessive vascular permeability inside eye tissues, dominated by neovascular age-related macular degeneration and macular edema triggered by central retinal vein occlusion. These chronic ocular conditions damage the central macular region responsible for sharp central vision, gradually impairing daily visual function and risking permanent blindness without sustained anti-angiogenic intervention. Traditional ocular treatments fail to specifically block abnormal vascular growth signals, while early anti-VEGF biologic agents present limited ligand binding range and require frequent repeated injections. Aflibercept, a fusion protein therapeutic often termed VEGF Trap-Eye, delivers broad-spectrum inhibition of angiogenic signaling molecules and has become a mainstream intravitreal injection therapy for the above retinal conditions. Its unique molecular structure delivers longer-lasting target suppression relative to comparable anti-VEGF biologics, yet individual patient drug exposure and immune response profiles vary widely across treatment cycles.
Figure 1.Precision Monitoring of Aflibercept Therapy.
Underlying retinal pathology stems from overproduction of vascular endothelial growth factor family proteins and placental growth factor within damaged retinal tissue. These signaling molecules bind to endothelial cell surface receptors, triggering uncontrolled new blood vessel formation, fluid leakage into retinal layers, macular thickening, and irreversible photoreceptor damage. Aflibercept functions as a soluble decoy receptor engineered by fusing extracellular binding domains of two human VEGF receptors with the constant fragment of human IgG1 immunoglobulin. It binds multiple angiogenic ligands with enhanced affinity compared to native cellular receptors, competitively sequestering growth factors before they can activate retinal endothelial signaling cascades. This blockade suppresses abnormal vessel proliferation and vascular leakage simultaneously, stabilizing macular anatomy and preserving visual function for treated patients.
Therapeutic efficacy relies on consistent presence of unbound active aflibercept within systemic circulation and ocular compartments; insufficient circulating drug diminishes target inhibition capacity and accelerates clinical disease recurrence, highlighting the necessity of quantitative drug level testing for research cohort analysis.
Aflibercept functions as a soluble VEGF decoy receptor, constructed through recombinant fusion of ligand-binding extracellular domains from human VEGFR1 and VEGFR2, linked to the constant Fc fragment of human IgG1 immunoglobulin. This structural design delivers two key functional advantages over alternative anti-VEGF therapeutic proteins. First, the composite receptor domains deliver markedly higher binding affinity for VEGF-A compared to monoclonal antibody-based anti-VEGF agents, enabling potent sequestration of circulating ligand before it engages native endothelial cell receptors. Second, aflibercept uniquely binds placental growth factor (PlGF) and VEGF-B alongside VEGF-A, blocking a broader spectrum of pro-angiogenic signalling pathways that sustain retinal neovascularisation and vascular permeability. Once bound to aflibercept, VEGF ligands cannot initiate intracellular tyrosine kinase signalling cascades required for endothelial proliferation, vessel sprouting, and barrier breakdown.
| Target Ocular Pathologies and VEGF-Mediated Pathology | Detail |
| Neovascular Age-Related Macular Degeneration | In aging retinas, metabolic stress and chronic inflammatory signalling trigger excessive VEGF release beneath the retinal pigment epithelium. This signalling cascade stimulates abnormal sprouting of fragile choroidal blood vessels that penetrate the retinal barrier. These immature vessels lack structural integrity, leading to persistent fluid leakage, subretinal haemorrhage, and progressive destruction of the central macular photoreceptor layer responsible for sharp central vision. Without targeted anti-angiogenic intervention, irreversible central scotoma and permanent vision loss develop over time. |
| Central Retinal Vein Occlusion with Macular Edema | Retinal venous outflow blockage induces widespread tissue ischaemia, which upregulates local VEGF production as a compensatory vascular repair signal. Elevated VEGF disrupts tight endothelial junctions lining retinal capillaries, breaking down the blood-retinal barrier and causing diffuse fluid accumulation within the macular tissue. The resultant macular swelling distorts photoreceptor alignment, producing blurring, metamorphopsia, and loss of fine visual resolution. Aflibercept suppresses VEGF-driven permeability and angiogenesis to resolve oedema and stabilise visual function. |
| Product Name | Purpose | Sample Type | Key Application |
| Aflibercept ELISA Kit | Quantification of Aflibercept drug concentration | Serum, Plasma | Therapeutic drug level monitoring |
| Anti-Aflibercept ELISA Kit | Detection of anti-Aflibercept antibodies | Serum, Plasma | Immunogenicity assessment |
Aflibercept occupies a central role in managing VEGF-mediated degenerative retinal disorders, yet interpatient variability in systemic drug exposure and variable immune response generation create substantial complexity in interpreting individual treatment trajectories. Precision translational monitoring relies on two interconnected analytical endpoints: quantitative free aflibercept measurement and anti-drug antibody quantification to assess immunogenic risk. The paired ELISA assay systems from Creative Diagnostics deliver validated, high-throughput analytical tools purpose-built for human serum and plasma biomarker research, offering matching laboratory handling protocols while specialised target capture designs separate drug quantitation and antibody screening workflows. Utilisation of both kits in parallel specimen analysis enables comprehensive, multi-dimensional evaluation of aflibercept therapy, supporting advances in dosing optimisation, biosimilar comparability trials, and long-term safety and immunogenicity research for anti-VEGF retinal therapeutics. All products remain strictly confined to laboratory investigative applications and are not authorised for clinical diagnostic use in patient care pathways.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIAZ0044 | Aflibercept ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIAZ0045 | Anti-Aflibercept ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| VEGF | CABT-Z819H | Human Anti-Human VEGF (Aflibercept) Monoclonal Antibody, clone Aflibercept [Biosimilar] | Human | IgG1 | FA | Inquiry |
Loading ......
